Hunan Julhakyan

Dr. Hunan Julhakyan

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2021 in Clinical Lymphoma Myeloma and Leukemia
Verified
Journal Article
Closed access
SSSvetlana Yu. Smirnova
Svetlana Yu. Smirnova
LALyubov S. Al-Radi
Lyubov S. Al-Radi
TMTatyana N. Moiseeva
Tatyana N. Moiseeva
EGEduard G. Gemdzhian
Eduard G. Gemdzhian
IYIgor A. Yakutik
Igor A. Yakutik
ASAndrey Sudarikov
Andrey Sudarikov

1 May 2020 in Clinical Lymphoma Myeloma and Leukemia
Verified
Journal Article
Closed access
APAnna Petrova
Anna Petrova
ECEkaterina Chelysheva
Ekaterina Chelysheva
OSOleg Shukhov
Oleg Shukhov
ABAnastasiya Bykova
Anastasiya Bykova
INIrina Nemchenko
Irina Nemchenko
ATAnna Turkina
Anna Turkina

1 April 2020 in Clinical Lymphoma Myeloma and Leukemia
Verified
Journal Article
Closed access
YSYulia Sidorova
Yulia Sidorova
KSKseniya A. Sychevskaya
Kseniya A. Sychevskaya
NCNataliya G. Chernova
Nataliya G. Chernova
HJHunan Julhakyan
Hunan Julhakyan
SSSvetlana Ju. Smirnova
Svetlana Ju. Smirnova
ASAndrey Sudarikov
Andrey Sudarikov

1 August 2016 in Clinical Lymphoma Myeloma and Leukemia
Verified
Journal Article
Closed access
HJHunan Julhakyan
Hunan Julhakyan
LAL.S. Al-Radi
L.S. Al-Radi
TMT.N. Moiseeva
T.N. Moiseeva
KDK.I. Danishyan
K.I. Danishyan
AKAlla Mikhailovna Kovrigina
Alla Mikhailovna Kovrigina
VSV.G. Savchenko
V.G. Savchenko

10 May 2022 in Current Oncology
Verified
Journal Article
Open access
PDF file
NRNatalya Risinskaya
Natalya Risinskaya
YMYana Mangasarova
Yana Mangasarova
ENElena Nikulina
Elena Nikulina
YKYana Kozhevnikova
Yana Kozhevnikova
CYChabaeva Yulia
Chabaeva Yulia
ASAndrey Sudarikov
Andrey Sudarikov
Primary mediastinal B-cell lymphoma (PMBCL) is the only non-Hodgkin’s lymphoma variant responding to immune checkpoint inhibitor (ICI) therapy, approximately in half of the cases; however, no molecular markers predicting a response to ICI therapy in PMBCL have been described so far. In this study, we assessed the incidence of the loss of heterozygosity (LOH), elevated microsatellite alteration at selected tetranucleotides (EMAST), and microsatellite instability (MSI) in the tumor genomes of 72 patients with PMBCL undergoing high-dose chemotherapy treatment at the National Research Center for Hematology (Moscow, Russia). Tumor DNA was isolated from biopsy samples taken at diagnosis. Control DNA was isolated from the blood of patients in complete remission or from buccal epithelium. STR-profiles for LOH and EMAST were assessed by PCR with COrDIS Plus multiplex kit (Gordiz Ltd., Moscow, Russia). LOH was detected in 37 of 72 patients (51.4%). EMAST was found in 40 patients (55.5%); 24 had a combination of EMAST with LOH. MSI-high was not found, while MSI-low was detected only in one patient. The association of certain genetic lesions with the clinical outcome in patients receiving treatment according to the standard clinical protocol R-Da-EPOCH-21 has been estimated (58 patients out of 72) and no associations with the worst overall or event-free survival were found.

23 February 2022 in Genes
Verified
Journal Article
Open access
PDF file
NRNatalya Risinskaya
Natalya Risinskaya
YKYana Kozhevnikova
Yana Kozhevnikova
OAOlga Aleshina
Olga Aleshina
CYChabaeva Yulia
Chabaeva Yulia
EKEkaterina Kotova
Ekaterina Kotova
EPElena Parovichnikova
Elena Parovichnikova
Despite the introduction of new technologies in molecular diagnostics, one should not underestimate the traditional routine methods for studying tumor DNA. Here we present the evidence that short tandem repeat (STR) profiling of tumor DNA relative to DNA from healthy cells might identify chromosomal aberrations affecting therapy outcome. Tumor STR profiles of 87 adult patients with de novo Ph-negative ALL (40 B-ALL, 43 T-ALL, 4 mixed phenotype acute leukemia (MPAL)) treated according to the “RALL-2016” regimen were analyzed. DNA of tumor cells was isolated from patient bone marrow samples taken at diagnosis. Control DNA samples were taken from the buccal swab or the blood of patients in complete remission. Overall survival (OS) analysis was used to assess the independent impact of the LOH as a risk factor. Of the 87 patients, 21 were found with LOH in various STR loci (24%). For B-ALL patients, LOH (except 12p LOH) was an independent risk factor (OS hazard ratio 3.89, log-rank p-value 0.0395). In contrast, for T-ALL patients, the OS hazard ratio was 0.59 (log-rank p-value 0.62). LOH in particular STR loci measured at the onset of the disease could be used as a prognostic factor for poor outcome in B-ALL, but not in T-ALL.